Corpura Fondkommission AB är finansiell rådgivare i samband med DanCann Pharma A/S övertecknade noteringsemission av units.

Den 23 oktober 2020 avslutades teckningstiden i DanCann Pharmas A/S:s noteringsemission av units inför notering på Spotlight Stock Market. Emissionen om cirka 30 MDKK tecknades till cirka 55 MDKK vilket motsvarar en teckningsgrad om cirka 183 % och där den publika delen av noteringsemissionen tecknades till cirka 433%. DanCann Pharma tillförs därmed totalt cirka 30 MDKK före emissionskostnader. DanCann Pharma kan tillföras cirka 16 MDKK ytterligare vid optionslösen i augusti 2021.

DanCann Pharmas VD Jeppe Krog Rasmussen kommenterar:
” I would like to start by thanking everyone who has shown interest in DanCann Pharma by participating in the Company’s IPO. We are very pleased with the result of the capital raising and are now looking forward to driving the Company forward using the funds raised to help patients in need of alternative treatment.

An exciting future awaits us, both as an employee, stakeholder, and shareholder – and on behalf of the Company, I look forward to the future communication in terms of the Company’s many exciting upcoming milestones and achievements.”

Kort om DanCann Pharma
DanCann Pharma was founded in 2018 and is a Danish pharmaceutical biotechnology company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed cultivation and distribution company based in Denmark. The company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

För mer information www.corpura.se eller kontakta:
Alexander Kangas, telefon 0722- 52 34 51
alexander.kangas@corpura.se